Ignite Creation Date:
2024-05-06 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 12:55 PM
Study NCT ID:
NCT03691376
Status:
TERMINATED
Last Update Posted:
2024-03-12
First Post:
2018-09-27
Brief Title:
Genetically Engineered Cells NY-ESO-1 TCR Engineered T Cells and HSCs After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-08
Start Date Type:
ACTUAL
Primary Completion Date:
2021-01-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-01-24
Completion Date Type:
ESTIMATED
First Submit Date:
2018-09-27
First Submit QC Date:
September 28 2018
Study First Post Date:
2018-10-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-06
Last Update Post Date:
2024-03-12
Last Update Post Date Type:
ACTUAL